# US 2022/0016029 A1 · Multi-peg lipid compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016029 A1
- Document ID: US20220016029A1
- Status: Published application
- Kind: A1
- Application number: 17/291,923
- Filed: 2019-11-07
- Published: 2022-01-20
- Earliest claimed: 2018-11-09
- Assignees: Translate Bio, Inc.
- Applicants: Translate Bio, Inc.
- Inventors: Shrirang Karve; Yi Zhang; Frank DeRosa; Michael Heartlein
- Web page: https://patentgrep.com/patent/US20220016029A1

## CPC

- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- C08G 65/33303: {containing amino group}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6911: {the form being a liposome}
- A61P 11/00: Drugs for disorders of the respiratory system
- C08G 65/3311: {containing a hydroxy group}
- C08G 65/332: containing carboxyl groups, or halides, or esters thereof
- C08G 65/3322: {acyclic}
- C08G 65/33306: {acyclic}
- C08G 65/3356: {having nitrogen in addition to phosphorus}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The compounds disclosed herein (e.g., compounds of Formula (I), (II), (III), and (IV)) comprise a lipid substructure comprising a hydrophobic moiety and a hydrophilic moiety; and two or more polymeric groups (e.g., two or more polyethylene glycol (PEG) groups). The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

## Claims

### Claim 1

A compound comprising
a lipid substructure comprising a hydrophobic moiety and a hydrophilic moiety; and
two or more polymeric groups.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the polymeric groups are selected from polyvinylalcohol, polyethylene glycol, polypropylene glycol, polyethylenimine, polyacrylic acid, polymethacrylic acid, polymethacrylate, polylysine, polyarginine, polyglutamic acid, dextran, a polypeptide, hyaluronic acid, alginate, chitosan, chitin, xylan, and pullulan.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, wherein the polymeric groups are polyethylene glycol (PEG) groups.

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein the lipid substructure comprises a ceramide lipid.

### Claim 5 (depends on 4)

The compound of claim 4, having a structure according to Formula (I),
wherein:
R1 and R2 are each independently C6-C24 aliphatic;
L is a linker group covalently bonded to each Z group;
each Z independently has a structure that is
each A1 is independently a covalent bond, O, or NRa;
each A2 is S—S, C(O), or C(S);
each Ra and each RZ are independently H or C1-C6 alkyl;
m is an integer having a value of 2 or more; and
each n is independently an integer having a value from 4 to 150.

### Claim 6 (depends on 5)

The compound of claim 5, having a structure according to Formula (I-A),
wherein:
each Z independently has a structure that is

### Claim 7 (depends on 6)

The compound of claim 6, wherein A1 is O.

### Claim 8 (depends on 5, 6, 7)

The compound of anyone of claims 5-7, wherein m is an integer having a value of 2, 3, 4, or 5.

### Claim 9 (depends on 8)

The compound of claim 8, wherein m is an integer having a value of 2.

### Claim 10 (depends on 5)

The compound of claim 5, wherein L-[Z]m has a structure that is
wherein,
X1 and X2 are each independently O or S;
X3 is independently a covalent bond, O, or S; and
y and z are integers, each independently having a value from 1 to 12.

### Claim 11 (depends on 5, 10)

The compound of claim 5 or 10, wherein L-[Z]m has a structure that is

### Claim 12 (depends on 10, 11)

The compound of claim 10 or 11, wherein X1 and X2 are each O.

### Claim 13 (depends on 10, 11, 12)

The compound of any one of claims 10-12, wherein y is 2.

### Claim 14 (depends on 10, 11, 12, 13)

The compound of any one of claims 10-13, wherein z is 1.

### Claim 15 (depends on 10, 11, 12, 13, 14)

The compound of any one of claims 10-14, wherein X3 is O.

### Claim 16 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The compound of any one of claims 5-15, wherein R1 and R2 are each independently selected from C6-C24-alkyl or C6-C24-alkenyl.

### Claim 17 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 5-16, wherein R1 and R2 are each independently selected from:
—(CH2)7CH3, —(CH2)9CH3, —(CH2)13CH3, —(CH2)14CH3, —(CH2)15CH3,
—(CH2)17CH3, —(CH2)19CH3, —(CH2)2, —CH3, —CH═CH(CH2)12CH3, and
—(CH2)6CH═CH(CH2)7CH3, and —(CH2)12CH═CH(CH2)7CH3.

### Claim 18 (depends on 17)

The compound of claim 17, wherein R1 is —CH═CH(CH2)12CH3.

### Claim 19 (depends on 17, 18)

The compound of claim 17 or 18, wherein R2 is —(CH2)7CH3.

### Claim 20 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any of claims 5-19, having the structure:

### Claim 21 (depends on 1, 2, 3)

The compound of any one of claims 1-3, having a structure according to Formula (III),
wherein:
R6 and R7 are each independently C6-C24 aliphatic;
L is a linker group covalently bonded to each Z group;
each Z independently has a structure that is
each A1 is independently a covalent bond, O, or NRa;
each A2 is S—S, C(O), or C(S);
each Ra and each RZ are independently H or C1-C6 alkyl;
m is an integer having a value of 2 or more; and
each n is independently an integer having a value from 4 to 150.

### Claim 22 (depends on 1, 2, 3, 21)

The compound of any one of claims 1-3 and 21, having a structure according to Formula (III-A),
wherein:
each Z independently has a structure that is

### Claim 23 (depends on 22)

The compound of claim 22, wherein A1 is NH.

### Claim 24 (depends on 21, 22, 23)

The compound of any one of claims 21-23, wherein m is an integer having a value of 2, 3, 4, or S.

### Claim 25 (depends on 24)

The compound of claim 24, wherein m is an integer having a value of 2.

### Claim 26 (depends on 21, 22)

The compound of claim 21 or 22, wherein L-[Z]m has a structure that is
wherein,
X2 is O or S; and
z is an integer having a value from 0 to 12.

### Claim 27 (depends on 26)

The compound of claim 26, wherein L-[Z]m has a structure that is

### Claim 28 (depends on 26, 27)

The compound of claim 26 or 27, wherein X2 is O.

### Claim 29 (depends on 26, 27, 28)

The compound of any one of claims 26-28, wherein z is O.

### Claim 30 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound of any one of claims 21-29, wherein R6 and R7 are each independently selected from C6-C24-alkyl or C6-C24-alkenyl.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The compound of any one of claims 21-30, wherein R6 and R7 are each independently selected from:
—(CH2)7CH3, —(CH2) CH3, —(CH2)13CH3, —(CH2)14CH3, —(CH2)15CH3,
—(CH2)17CH3, —(CH2)19CH3, —(CH2)21CH3, —CH═CH(CH2)12CH3,
—(CH2)6CH═CH(CH2)7CH3, and —(CH2)12CH═CH(CH2)7CH3.

### Claim 32 (depends on 31)

The compound of claim 31, wherein R6 is —(CH2)13CH3.

### Claim 33 (depends on 31, 32)

The compound of claim 31 or 32, wherein R7 is —(CH2)13CH3.

### Claim 34 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The compound of any of claims 21-33, having the structure:

### Claim 35 (depends on 1, 2, 3)

The compound of any one of claims 1-3, having a structure according to Formula (IV),
wherein:
each R1a and R2a is independently C6-C24-aliphatic;
R3 is independently
R4 is independently hydrogen,
R3a, R4a, and R5 are each independently selected from H or C1-C6-alkyl;
each n is independently an integer having a value from 4 to 150;
k is independently 0 or 1; and
each of k′ and k″ is independently an integer having a value from 1 to 12.

### Claim 36 (depends on 1, 2, 3, 35)

The compound of any one of claims 1-3 and 35, having the structure according to Formula (IV-A):

### Claim 37 (depends on 35, 36)

The compound of claim 35 or 36, wherein k is 1.

### Claim 38 (depends on 35, 36, 37)

The compound of any one of claims 35-37, wherein R3 is

### Claim 39 (depends on 35, 36, 37, 38)

The compound of any one of claims 35-38, wherein R4 is

### Claim 40 (depends on 35, 36, 37, 38, 39)

The compound of any one of claims 35-39, wherein R1a Is C14-alkyl.

### Claim 41 (depends on 35, 36, 37, 38, 39, 40)

The compound of any one of claims 35-40, wherein R2a is C14-alkyl.

### Claim 42 (depends on 35, 36, 37, 38, 39, 40, 41)

The compound of any one of claims 35-41, having the structure:

### Claim 43 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein the lipid substructure comprises a phospholipid.

### Claim 44 (depends on 1, 2, 3, 43)

The compound of any one of claims 1-3 and 43, having a structure according to Formula (II),
wherein:
R8 and R9 are each independently C6-C24-aliphatic;
L is a linker group covalently bonded each Z group;
each Z independently has a structure that is
each A1 is independently a covalent bond, O, or NRa;
each A2 is independently S—S, C(O), or C(S);
each Ra and each RZ are independently H or C1-C6 alkyl;
m is an integer having a value of 2 or more; and
n is an integer having a value from 4 to 150.

### Claim 45 (depends on 1, 2, 3, 43)

The compound of any one of claims 1-3, 43, and 44, having a structure according to Formula (II-A),
wherein:
each Z independently has a structure that is

### Claim 46 (depends on 44, 45)

The compound of claim 44 or 45, wherein m is an integer having a value of 2, 3, 4, or 5.

### Claim 47 (depends on 46)

The compound of claim 46, wherein m is an integer having a value of 2.

### Claim 48 (depends on 44, 45, 46, 47)

The compound of any one of claims 44-47, wherein L-[Z]m has a structure that is
wherein,
X2 is O or S;
each A1 is independently a covalent bond, O, or NRa;
each A2 is independently S—S, C(O), C(S), CO2, or C(O)NRa;
Ra is H or C1-C6 alkyl; and
z is independently an integer having a value from 0 to 12.

### Claim 49 (depends on 48)

The compound of claim 48, wherein z is 1.

### Claim 50 (depends on 48, 49)

The compound of claim 48 or 49, wherein L-[Z]m has a structure that is

### Claim 51 (depends on 48, 49, 50)

The compound of any one of claims 48-50, wherein X2 is O.

### Claim 52 (depends on 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 44-51, wherein at least one of R8 or R9 is C17-alkyl.

### Claim 53 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52)

The compound of any one of claims 44-52, wherein both of R8 and R9 are C17-alkyl.

### Claim 54 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The compound of any one of claims 44-53, having the structure:

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

A composition comprising an mRNA encoding a protein, encapsulated within a liposome, wherein the liposome comprises one or more compounds of claims 1-54.

### Claim 56 (depends on 55)

The composition of claim 55, comprising an mRNA encoding for cystic fibrosis transmembrane conductance regulator (CFTR) protein.

### Claim 57 (depends on 55)

The composition of claim 55, comprising an mRNA encoding for ornithine transcarbamylase (OTC) protein.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

A composition comprising a nucleic acid encapsulated within a liposome, wherein the liposome comprises one or more compounds of claims 1-54.

### Claim 59 (depends on 58)

The composition of claim 58, wherein the nucleic acid is an mRNA encoding a peptide or protein.

### Claim 60 (depends on 59)

The composition of claim 59, wherein the mRNA encodes a peptide or protein for use in the delivery to or treatment of the lung of a subject or a lung cell.

### Claim 61 (depends on 59)

The composition of claim 59, wherein the mRNA encodes cystic fibrosis transmembrane conductance regulator (CFTR) protein.

### Claim 62 (depends on 59)

The composition of claim 59, wherein the mRNA encodes a peptide or protein for use in the delivery to or treatment of the liver of a subject or a liver cell.

### Claim 63 (depends on 59)

The composition of claim 59, wherein the mRNA encodes ornithine transcarbamylase (OTC) protein.

### Claim 64 (depends on 55, 58)

The composition of claim 55 or 58, wherein the mRNA encodes a peptide or protein for use in vaccine.

### Claim 65 (depends on 64)

The composition of claim 64, wherein the mRNA encodes an antigen.
